Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 19

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 19
---
 therapeutic candidates due to a change in business strategies, or a merger, acquisition, sale or downsizing;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  a collaboration partner may seek to renegotiate                                                                                        
  or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy,  
  a change of control or other reasons;                                                                                                  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  a collaboration partner may cease development                               
  in therapeutic areas which are the subject of our strategic collaboration;  
 ──────────────────────────────────────────────────────────────────────────────

  a collaboration partner may not devote sufficient         
  capital or resources towards our therapeutic candidates;  
 ────────────────────────────────────────────────────────────

12

  a collaboration partner may change the success                                                    
  criteria for a therapeutic candidate, thereby delaying or ceasing development of such candidate;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────

  a significant delay in initiation of certain                                                                                            

  a collaboration partner could develop a                                                

  a collaboration partner with commercialization                                                                           
  obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  a collaboration partner with manufacturing                                                                        
  responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  a partner may exercise a contractual right  
  to terminate a strategic alliance;          
 ──────────────────────────────────────────────

  a dispute may arise between us and a partner                                                                                                   
  concerning the research, development or commercialization of a therapeutic candidate resulting in a delay in milestones, royalty payments      
  or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources;  
  and                                                                                                                                            
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  a partner may use our products or technology               
  in such a way as to invite litigation from a third party.  
 ─────────────────────────────────────────────────────────────

Under the Gloria License Agreement, Gloria is late in the payment of $2.4 million to
us for the